Ryvu Therapeutics (WAR:RVU) Net Interest Margin (Bank Only) %

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

WAR:RVU Ryvu Therapeutics SA WAR:RVU
66 GF Score
Price zł14.98
GF Value zł45.84
Valuation Possible Value Trap
! 3 Warning Signs
View Full Analysis

What is Ryvu Therapeutics Net Interest Margin (Bank Only) %?

Net Interest Margin (Bank Only) % only applies to banks.

WAR:RVU
66GF Score
Ryvu Therapeutics SA WAR:RVU
Net Interest Margin (Bank Only) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Ryvu Therapeutics (WAR:RVU) Overvalued in 2026?

Based on GuruFocus' analysis, Ryvu Therapeutics stock appears to be undervalued. The current stock price of zł14.98 is trading 67.3% below its estimated GF Value™ of zł45.84. GuruFocus considers Ryvu Therapeutics to be Possible Value Trap.

Key valuation signals for WAR:RVU:

  • Net Interest Margin (Bank Only) %:
  • GF Value™: zł45.84 vs. price of zł14.98 (67.3% below fair value)
  • GF Score™: 66/100 with 3 warning signs

No single metric tells the full story. See the WAR:RVU stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Ryvu Therapeutics Business Description

Other Exchanges 9Y4:Germany
Address Leona Henryka Sternbacha 2, Krakow, POL, 30-394
Ryvu Therapeutics SA is a company which is engaged in discovering and developing small molecule therapies that address oncology. Its product candidate SEL120, is a kinase inhibitor with potential for development in hematological malignancies and solid tumors. The pipeline products of the company are developed in the areas of kinases, cancer metabolism, synthetic lethality, and immuno-oncology pathways.
66GF Score

Get the complete analysis for WAR:RVU

Net Interest Margin (Bank Only) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

zł14.98
Price
zł45.84
GF Value